Scientists may soon shock cancer out of your body with low-power electricity
New research from Virginia Tech’s Fralin Biomedical Research Institute shows that low-intensity electrical pulse therapy could help prepare the tumor environment for the immune system to work better.
This therapy has not received as much attention as high-intensity therapy, which is commonly used to destroy tumors.
Historically, high-frequency irreversible electroporation (H-FIRE) has been deployed to eradicate tumor masses through targeted electrical disruption of malignant cell membranes.
While effective in direct cytotoxicity, this approach often spares peripheral tumor regions, leaving residual neoplastic activity.
Low-power electric pulses
However, H-FIRE elicits a markedly different physiological response in its sub-ablative form, delivered at reduced electrical intensity.
Rather than inducing immediate tumor cell death, sub-ablative H-FIRE facilitates rapid vascular remodeling within the tumor microenvironment.
In a controlled study on breast cancer, researchers found that blood vessels increased significantly within 24 hours after treatment. By day three, they also noticed a rise in the growth of lymphatic vessels.
These changes indicate that the tumor adapts its support system, which may improve the body’s ability to monitor and move immune cells.
Published in the Annals of Biomedical Engineering, the study documents a shift in focus from the tumor as a target of direct destruction to the tumor as a node of immunological engagement.
By increasing perfusion and lymphatic drainage routes, the modified environment may enable more efficient recruitment and deployment of cytotoxic T-cells and other immune effectors.
Lead author Dr. Jennifer Munson, director of the Fralin Biomedical Research Institute Cancer Research Center, said, “Sub-ablative H-FIRE doesn’t eliminate the tumor outright, but it appears to change the rules of engagement. We’re seeing signals that may direct immune cells more effectively to the tumor site through lymphatic pathways.”
Fighting cancer
The study further clarifies a previously underexplored dimension of electroporation-based therapy.
While earlier observations had hinted at enhanced immune activity in partially ablated tumor margins, the functional interplay with the lymphatic system remained poorly characterized.
By examining primary tumor sites and adjacent lymph nodes, the research team has illuminated a pathway by which sub-ablative pulse protocols could potentially enhance systemic immune response.
These outcomes have significant implications for integrative cancer therapy strategies.
There is a promising link between changes in blood vessel structure and cancer treatments like checkpoint inhibitors and adoptive cell transfer therapies. This offers valuable research opportunities that could lead to new treatments.
Support for the study was provided by multiple arms of the National Institutes of Health, including the National Cancer Institute, the National Center for Advancing Translational Sciences, and the National Institute of Biomedical Imaging and Bioengineering.
Munson notes that future research objectives will center on mapping the downstream immune responses activated by vascular remodeling and evaluating whether these responses can be amplified when sub-ablative H-FIRE is used in conjunction with existing immunomodulatory therapies.
Sub-ablative H-FIRE may not completely cure cancer, but it can help change the tumor environment. This shift may improve how well the immune system can fight the cancer. This is an important step in the ongoing development of cancer treatment options.
Source: Interesting Engineering
Lab-grown teeth could be the future of dentistry
Scientists may soon shock cancer out of your body with low-power electricity